A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome - 07/08/11
Abstract |
Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in which current therapeutic options fail to halt the progression of disease. We present 3 cases of refractory Sézary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CBC, CTCL, FDA, IL, MF, SS, TSEB
Plan
Funding sources: None. |
|
Disclosure: Dr Rook has lectured at events sponsored by Merck. Dr Kim was a study site investigator for a clinical trial involving vorinostat from 2004 to 2005. Drs Gardner, Introcaso, Nasta, and Vittorio have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 61 - N° 1
P. 112-116 - juillet 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?